Boosting Oncology Research with Artificial Intelligence
Artificial intelligence (AI) is rapidly transforming the field of oncology, enhancing the precision of cancer diagnostics and accelerating drug development processes. AI and machine learning
Artificial intelligence (AI) is rapidly transforming the field of oncology, enhancing the precision of cancer diagnostics and accelerating drug development processes. AI and machine learning
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic makeup.
A groundbreaking gene editing therapy for sickle cell disease from CRISPR Therapeutics and Vertex Pharmaceuticals has received approval from the U.S. Food and Drug Administration.
Gene therapy offers hope for treating a wide range of inherited and acquired diseases and conditions, ranging from muscular dystrophy to obesity. Gene therapy for
Hemophilia is a rare genetic blood disorder characterized by the absence or malfunction of blood clotting factors, which can lead to severe and sometimes life-threatening
Blood cancers like leukemia and lymphoma are caused by mutations in the DNA of blood cells. These mutations cause normal blood cells to change into cancer
Gene therapy for ocular disease is a rapidly evolving field with promise as a treatment option for various genetic and acquired eye diseases. It uses
Alzheimer’s disease is a major global health concern: the devastating neurodegenerative disorder is responsible for 60-80 percent of all cases of dementia, and it affects
Parkinson’s disease is a progressive neurodegenerative disorder with no known cure. Current treatment options are limited, aiming to alleviate some symptoms through a combination of
Despite being one of the world’s most common inherited blood disorders, sickle cell disease has few treatment options, even with the approval of three new
The recent release of findings from a small Phase 1 clinical trial not only gives hope to families affected by an ultra-rare childhood disease, but
Contract research organizations (CROs) have been an integral part of drug development since the 1920s, first as providers of preclinical testing services, then as organizations
Artificial intelligence (AI) is rapidly transforming the field of oncology, enhancing the precision of cancer diagnostics and accelerating drug development processes. AI and machine learning
Leveraging rapid developments in gene therapy, researchers are designing new ways to target ultra-rare genetic diseases with treatments tailored to a patient’s specific genetic makeup.
A groundbreaking gene editing therapy for sickle cell disease from CRISPR Therapeutics and Vertex Pharmaceuticals has received approval from the U.S. Food and Drug Administration.
Gene therapy offers hope for treating a wide range of inherited and acquired diseases and conditions, ranging from muscular dystrophy to obesity. Gene therapy for
Hemophilia is a rare genetic blood disorder characterized by the absence or malfunction of blood clotting factors, which can lead to severe and sometimes life-threatening
Blood cancers like leukemia and lymphoma are caused by mutations in the DNA of blood cells. These mutations cause normal blood cells to change into cancer
Gene therapy for ocular disease is a rapidly evolving field with promise as a treatment option for various genetic and acquired eye diseases. It uses
Alzheimer’s disease is a major global health concern: the devastating neurodegenerative disorder is responsible for 60-80 percent of all cases of dementia, and it affects
Parkinson’s disease is a progressive neurodegenerative disorder with no known cure. Current treatment options are limited, aiming to alleviate some symptoms through a combination of
Despite being one of the world’s most common inherited blood disorders, sickle cell disease has few treatment options, even with the approval of three new
The recent release of findings from a small Phase 1 clinical trial not only gives hope to families affected by an ultra-rare childhood disease, but
Contract research organizations (CROs) have been an integral part of drug development since the 1920s, first as providers of preclinical testing services, then as organizations
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
Emails are serviced by Constant Contact. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.